Crush technique
ProcedureCrush technique
Other names: Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents
NCT Number: NCT00693251
It is unclear which stenting strategy will be optimal for true bifurcation coronary lesions.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 4
Soonchunhyang University Bucheon Hospital, Bucheon-si, South Korea
The outcome of percutaneous coronary intervention of bifurcation lesions with bare-metal stents is hindered by increased rates of procedural complications and long-term major adverse cardiac events compared with non-bifurcated lesions.1 Randomized studies have demonstrated that drug-eluting stents reduce restenosis when used in relatively simple lesions; and recent data have demonstrated efficacy of the sirolimus-eluting stent for bifurcation lesions compared with historical data of BMS. In one study of bifurcation lesions, the overall restenosis rate was 23%, with the majority of side branch restenoses occurring at the ostium after use of a T-stenting technique. Indeed, side branch restenosis occurred in 16.7% after T-stenting, compared with 7.1% after other stenting techniques.
The "crush" technique of bifurcation stenting with DESs was introduced by Colombo et al. in 2003 as a relatively simple technique that ensures complete coverage of the side branch ostium, thereby facilitating drug delivery at this site. Initial data of 20 patients treated with this technique with SES suggest that it is a safe method, with an acceptable rate of procedural complications and no further adverse events up to 30 days follow-up. Recently, angiographic data have shown the importance of simultaneous kissing balloon post-dilation in reducing restenosis and need for target lesion revascularization. They also reported that compared to T-stenting, crushing with final kissing balloon dilatation was associated with lower rate of restenosis and target lesion revascularization. Consequently, the crushing is currently most promising technique in treating bifurcation lesions using two stents. However, despite the advance of bifurcation stenting technique, the superiority of bifurcation stenting with crushing technique over simple stenting in bifurcation lesion has not been demonstrated.
Therefore, we conducted the prospective randomized study comparing crushing technique with final kissing balloon dilatation and a simple technique (main vessel stenting and provisional T-stenting) for treatment of true bifurcation lesions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Crush technique
Other names: Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents
Provisional T stenting
Other names: Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents
Time frame: 8 months
Time frame: 2 years
Time frame: 8 months
Time frame: 8 months
Time frame: 8 months
Time frame: 8 months
Time frame: 8 months
Time frame: baseline
Time frame: baseline
Time frame: baseline
Time frame: baseline
Time frame: baseline and 8 months
Seung-Jung Park
Other
Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions
Acronym: PERFECT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06154265
Arterial Occlusive Diseases, Arteriosclerosis
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07551518
Algorithm Validation for Fractional Flow Reserve Derived From Intravascular Ultrasound, Arterial Occlusive Diseases
Beijing, Select, China
View Trial DetailsNCT04475380
Acute Coronary Syndrome, Angina Pectoris
Enschede, Netherlands
View Trial DetailsNCT06039748
Arterial Occlusive Diseases, Arteriosclerosis
Jieyang, Guangdong, China
View Trial Details